Regeneron

Regeneron Pharmaceuticals . is a biotechnology company headquartered in Tarrytown, New York. Founded in 1988, it researches and develops therapies for serious medical conditions luding ophthalmology, immunology, and oncology. Its core products lude Eylea for retinal diseases and Dupixent for inflammatory conditions, co‑developed with Sanofi, along with a broad pipeline of oncology biologics. The company operates manufacturing and R&D facilities in the U.S. and Europe and collaborates with global partners on genomics‑based drug discovery. Regeneron complies with FDA and ISO 13485 regulations and executes ESG initiatives focused on bioethical research and biomanufacturing sustainability. In 2024, it recorded $13.8 billion in revenue (+9% year‑on‑year) and $4.1 billion in net ome. Regeneron continues to invest in expanding its antibody platform and genomic research infrastructure to accelerate precision‑medicine development.